GlassScriptPhysician profile
Reem Tadros
NPI 1205934213
$5,105.27
in general payments reported to CMS, 2019-2025
22 companies · $1,292 in 2025
The $1,292 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $43.31 · 2021: $136 · 2022: $642 · 2023: $1,310 · 2024: $1,518 · 2025: $1,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,921 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,921.06 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $825.15 | 2019-2025 | Tremfya |
| Leo Pharma INC. | $643.78 | 2019-2025 | Adbry, Anzupgo |
| Abbvie INC. | $506.52 | 2019-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $504.18 | 2021-2025 | Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $498.73 | 2022-2025 | Sotyktu |
| Pfizer INC. | $292.50 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $272.23 | 2021-2025 | |
| Lilly USA, LLC | $243.58 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $200.85 | 2022-2024 | Vtama |
| Incyte Corporation | $198.38 | 2021-2025 | Opzelura |
| Genzyme Corporation | $178.08 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $115.78 | 2023-2025 | Dupixent, Libtayo |
| Amgen INC. | $114.40 | 2024-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $94.43 | 2020-2023 | Aklief, Oracea, Epsolay |
| Almirall LLC | $83.06 | 2023-2025 | Seysara, Klisyri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $69.64 | 2023-2024 | Zoryve |
| Ucb, INC. | $59.68 | 2023-2024 | Bimzelx |
| Botanix Sb INC | $47.83 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $43.91 | 2024-2025 | Xtrac |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.10 | 2019-2025 | Siliq, Jublia, Cabtreo |
| Verrica Pharmaceuticals INC. | $37.08 | 2023-2024 | Ycanth |
| Organon LLC | $32.38 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reem Tadros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.